簡要描述:乳腺腺癌標志物CHMP2A抗體注意事項;This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. Function: Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Involved in HIV-1 p6- and p9-dependent virus release.
產品分類
Product Category相關文章
Related Articles詳細介紹
商品屬性:
貨號 | 產品名稱 | 規(guī)格 |
GOY-01K0379 | 乳腺腺癌標志物CHMP2A抗體 | 50ul |
GOY-01K0379 | 乳腺腺癌標志物CHMP2A抗體 | 100ul |
GOY-01K0379 | 乳腺腺癌標志物CHMP2A抗體 | 200ul |
英文名稱: CHMP2A
中文名稱: 乳腺腺癌標志物CHMP2A抗體
別 名;BC2; Charged multivesicular body protein 2a;
CHM2A_HUMAN; CHMP2; CHMP2a; Chromatin modifying protein 2a; Chromatin-modifying
protein 2a; hVps2 1; hVps2-1; putative breast adenocarcinoma marker; Putative
breast adenocarcinoma marker BC-2; Putative breast adenocarcinoma marker BC2;
Vacuolar protein sorting associated protein 2 1; Vacuolar protein
sorting-associated protein 2-1; Vps2 1; VPS2; Vps2-1; VPS2.
研究領域;腫瘤 細胞生物 信號轉導 細胞周期蛋白
抗體來源;Rabbit
克隆類型;Polyclonal
交叉反應;(predicted: Human, Mouse, Rat,
Dog, Sheep, )
產品應用;WB=1:500-2000
ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 (石蠟切片需做抗原修復)
not yet tested in
other applications.
optimal
dilutions/concentrations should be determined by the end user.
理論分子量;25kDa
細胞定位;細胞核 細胞漿
性 狀;Liquid
濃 度;1mg/ml
免 疫 原;KLH conjugated synthetic
peptide derived from human CHMP2A: 1-100/222
亞 型;IgG
純化方法;affinity purified by Protein A
緩 沖 液;0.01M TBS(pH7.4) with 1% BSA,
0.03% Proclin300 and 50% Glycerol.
保存條件;Shipped at 4℃. Store at -20 °C for one year. Avoid
repeated freeze/thaw cycles.
注意事項;This product as supplied is
intended for research use only, not for use in human, therapeutic or diagnostic
applications.
Function:
Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Involved in HIV-1 p6- and p9-dependent virus release.
實驗流程:
(1)特異性結合抗原:抗體本身不能直接溶解或殺傷帶有特異抗原的靶細胞,通常需要補體或吞噬細胞等共同發(fā)揮效應以清除病原微生物或導致病理損傷。然而,抗體可通過與病毒或毒素的特異性結合,直接發(fā)揮中和病毒的作用。
(2)活補體:IgM、IgG1、IgG2和IgG3可通過經典途徑激活補體,凝聚的IgA、IgG4和IgE可通過替代途徑激活補體。
(3)結合細胞:不同類別的免疫球蛋白,可結合不同種的細胞,參與免疫應答。
(4)可通過胎盤及粘膜:免疫球蛋白G(IgG)能通過胎盤進入胎兒血流中,使胎兒形成自然被動
免疫。免疫球蛋白A(IgA)可通過消化道及呼吸道粘膜,是粘膜局部抗感染免疫的主要因素。
(5)具有抗原性:抗體分子是一種蛋白質,也具有刺機體產生免疫應答的性能。不同的免疫球蛋白分子,各具有不同的抗原性。
(6)抗體對理化因子的抵抗力與一般球蛋白相同:不耐熱,60~70℃即被破壞。各種酶及能使蛋白質凝固變性的物質,均能破壞抗體的作用??贵w可被中性鹽類沉淀。在生產上??捎昧蛩徜@或硫酸鈉從免疫血清中沉淀出含有抗體的球蛋白,再經透析法將其純化。
抗體的制備過程:
1. 乳腺腺癌標志物CHMP2A抗體免疫原:普通的大分子蛋白,通過分子克隆構建載體并在大腸桿菌中進行誘導表達獲得重組蛋白,純化鑒定后可直接作為免疫原;小分子蛋白或化合物等分子量小,需要偶聯(lián)載體對該分子進行改造才能使其成為具有免疫原性的抗原,常見偶聯(lián)載體如BSA、OVA、HAS等。
2. 免疫動物:常用于制備抗血清的動物有豚鼠、家兔、雞、大小鼠等,大量生產時需要用到狗、綿羊、山羊等。
3. 免疫血清的收集:一般家兔、綿羊、山羊可采用靜動脈采血,家兔、豚鼠、大鼠、雞可采用心臟采血,家兔、山羊、綿羊可采用靜脈采血。
4. 免疫血清的純化與鑒定:得到的抗血清需要進一步的純化,利用偶聯(lián)了抗原的親和柱進行層析,具有高效,特異性強,純度高的特定。接著要鑒定純化蛋白的含量、相對分子的質量、純度以及特異性。
5. 免疫血清的保存:抗體一般比較穩(wěn)定,在-80℃ ~-20 ℃可以保存約5年而不會影響效價,而真空干燥保存時間可以更久。保存前需經除菌并添加防腐劑。
產品咨詢
歡迎您關注我們的微信了解更多信息
電話
微信掃一掃